Trial · NCT02973269
DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
NCT02973269, Phase 2, Terminated, Revance Therapeutics, Inc.; results first posted 2024-04-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis. Trials, record NCT02973269. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02973269
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
- NCT number
- NCT02973269
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 7 participants, actual
- Lead sponsor
- Revance Therapeutics, Inc.
- Conditions
- Plantar Fasciitis
- Interventions
- daxibotulinumtoxin type A, Placebo
- First posted
- 2016-11-25
- Last updated
- 2024-04-03
- Results first posted
- 2024-04-03
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Improvement in the American Orthopaedic Foot and Ankle Score (AOFAS) | 16 weeks | The American Orthopaedic Foot and Ankle Score (AOFAS) is a 9-item questionnaire that evaluates pain, function, and alignment of the foot and ankle. The total score ranges from 0 to 100, with lower scores representing greater pain and disability, and higher scores representing better function. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Improvement in the American Orthopaedic Foot and Ankle Score (AOFAS) | 16 weeks | The Intent-to-Treat population includes all patients randomized to treatment. | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Improvement in the American Orthopaedic Foot and Ankle Score (AOFAS) | DAXI 240 U | 81.3 | Standard Deviation 11.0 | units on a scale | |
| Improvement in the American Orthopaedic Foot and Ankle Score (AOFAS) | Placebo | 86.5 | Standard Deviation 12.1 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | DAXI 240 U | 3 | |
| Overall Study | STARTED | Placebo | 4 | |
| Overall Study | COMPLETED | DAXI 240 U | 3 | |
| Overall Study | COMPLETED | Placebo | 4 | |
| Overall Study | NOT COMPLETED | DAXI 240 U | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Weakness | Musculoskeletal and connective tissue disorders | DAXI 240 U | 0 | 3 | 0 |
| other | Weakness | Musculoskeletal and connective tissue disorders | Placebo | 1 | 4 | 1 |
| other | Muscle cramps | Musculoskeletal and connective tissue disorders | DAXI 240 U | 1 | 3 | 1 |
| other | Muscle cramps | Musculoskeletal and connective tissue disorders | Placebo | 0 | 4 | 0 |
| other | Headache | Nervous system disorders | DAXI 240 U | 1 | 3 | 1 |
| other | Headache | Nervous system disorders | Placebo | 0 | 4 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | DAXI 240 U | 0 | 3 |
| Total, all-cause mortality | Placebo | 0 | 4 |
| Total, other adverse events | DAXI 240 U | 1 | 3 |
| Total, other adverse events | Placebo | 1 | 4 |
| Total, serious adverse events | DAXI 240 U | 0 | 3 |
| Total, serious adverse events | Placebo | 0 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| DAXI 240 U vs Placebo: deaths from any cause | Trial comparisons |
| DAXI 240 U vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02973269
GET https://conductscience.org/api/trials/v1/NCT02973269/registered